Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-20 11:46 CEST (UTC+2h)

GMP: EMA and FDA – mutual recognition of inspections [GxP / QC / QA]

posted by ElMaestro - Denmark, 2017-11-10 19:10  - Posting: # 17970
Views: 916

Hi all,

I am so worried because of all this.

They make it sound like unnecessary inspections are the big problem and that this agreement is the method to get rid of the problem. It sounds right, sensible use of resources, almost LEAN, tax payers money at work, blahblahblah.

But in fact I have never heard of unnecessary inspections, not even when FDA and EMA 'by chance' have been at the same place more or less simultaneously. Especially not when FDA and EMA 'by chance' have been at the same place more or less simultaneously, actually.

I am totally afraid this means less inspections overall, and that would absolutely be a step in the wrong direction. Fraud is on the rise and it is big business - as it is now, it makes good sense to cheat or cut corners because the chance of getting caught is small to state it bluntly. The financial gain is extremely high, unless you just happen to be unlucky enough to get caught.

You will see me happy and singing and dancing when I see inititative towardsA good weekend to all of you.

if (3) 4

Best regards,

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,397 posts in 3,909 threads, 1,175 registered users;
online 38 (2 registered, 36 guests [including 23 identified bots]).

The analysis of variance is not a mathematical theorem,
but rather a convenient method of arranging the arithmetic.    R.A. Fisher

BEBAC Ing. Helmut Schütz